Epogen news from FiercePharma
News
New drug-spending leader: Diabetes
New data on pharma sales details some big shifts in spending. Diabetes meds have displaced cholesterol drugs as the Read more...
AZ, Amgen earnings flat; Shire sales leap
It's a mixed bag of drugmaker earnings reports today, with two biggies posting flat results and two smaller firms chalking up respectable gains.AstraZeneca's profits suffered under restructuring Read more...
Mircera judge seeks expert guidance
The judge refereeing the turf battle between Roche and Amgen over anemia meds has taken a time-out to consult the experts. Judge William Young said he's grappling "with complex issues" in the patent Read more...
Amgen: Mircera deal would set precedent
Should he or shouldn't he? The judge weighing the case of Amgen v. Roche is getting a lot of unsolicited advice on whether to allow Roche's anemia med Mircera onto the market. Last year, a jury ruled Read more...
FDA panel votes to restrict anemia drugs
Look on the bright side: It could have been worse. An FDA advisory panel voted to keep Amgen and Johnson & Johnson's anemia remedies on the market for cancer patients. So the drugs appear to have Read more...
Judge blocks Roche's Mircera--for now
Victory for Amgen--and maybe for Roche, too. The California drug maker persuaded a judge to temporarily ban Roche's competing anemia drug Mircera in the U.S. But the judge also said he'd consider Read more...
Study: Anemia meds hike death risk 10%
The drumbeat of data is getting louder. A new analysis of the blockbuster anemia drugs sold by Amgen and Johnson & Johnson concludes they raise the risk of death among cancer patients by about 10 Read more...
Medicare: Right to restrict anemia meds
A Medicare official says there's an even better case now for restricting payments for Amgen Read more...
FDA: More risks from anemia drugs
The FDA dealt another blow to embattled anemia drugs yesterday. The agency revealed two new Read more...
Study finds link from ESAs to leukemia
In another blow to anemia drugs, Mayo Clinic researchers announced today that erythropoiesis-stimulating agents--like Amgen's Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight